Quest PharmaTech (QPT) Stock Price, News & Analysis

Company Overview

Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Key Stats

• Today's Range: C$0.04 to C$0.04
• 50-Day Range: C$0.03 to C$0.06
• 52-Week Range: C$0.02 to C$0.06
• Volume: 1,000 shs
• Average Volume: 78,791 shs
• Market Capitalization: C$5.92 million
• P/E Ratio: N/A
• Dividend Yield: 6.15%
• Price Target: N/A
• Consensus Rating: N/A

QPT Stock Analysis - Frequently Asked Questions

How have QPT shares performed this year?

Quest PharmaTech's stock was trading at C$0.03 at the start of the year. Since then, QPT stock has increased by 16.7% and is now trading at C$0.04.
View the best growth stocks for 2025 here.

How do I buy shares of Quest PharmaTech?

Shares of QPT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Quest PharmaTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quest PharmaTech investors own include Cameco (CCJ), Indiva (NDVA), Titan Medical (TMD), Aurinia Pharmaceuticals (AUP), Athenex (ATNX), Athersys (ATHX) and Antibe Therapeutics (ATE).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:QPT
• CIK: N/A
• Web: www.questpharmatech.com
• Phone: +1-780-4481400
• Fax: N/A
• Employees: 147,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-2,880,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -6.28%
• Return on Assets: -1.07%

Debt

• Debt-to-Equity Ratio: 4.35
• Current Ratio: 0.40
• Quick Ratio: 0.52

Sales & Book Value

• Annual Sales: C$38,871.00
• Price / Sales: 152.29
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 20.00
• Book Value: C$0.14 per share
• Price / Book: 0.25

Miscellaneous

• Outstanding Shares: 169,130,000
• Free Float: N/A
• Market Cap: C$5.92 million
• Optionable: Not Optionable
• Beta: 0.14